Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
701 (USA) · Dr. Reyes
consented 2013-07-19
AEs
2
Serious
0
Dropout signal
–
Adverse events
mild
assessed
Mild APPLICATION SITE ERYTHEMA — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-07-21 (study day 3.0); relationship: POSSIBLE
mild
assessed
Mild APPLICATION SITE PRURITUS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2013-08-08 (study day 21.0); relationship: PROBABLE
Data queries
No data queries.